Advertisement

Topics

U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome

08:43 EDT 24 Oct 2017 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Company announcement - No. 48/2017 U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome Copenhagen, Denmark, October 24, 2017 - The U.S. Food and Drug Administration (FDA) Office of Orph...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...